Template:Affinities of bicalutamide at steroid hormone receptors
Jump to navigation
Jump to search
Compound | AR | PR | ER | GR | MR |
---|---|---|---|---|---|
Template:No selflink | 14–54 | 3,500–7,200 | >1,000,000 | 44,000–320,000 | ≥360,000 |
Template:No selflink | 0.5–3.1 | 280–440 | 38,000–340,000 | 2,700–20,000 | 2,100–2,300 |
Notes: Values are Ki or IC50 (nM) for binding inhibition (affinity). Sources: [1][2][3][4] |
References
- ↑ Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N (November 2003). "Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis". Biol. Pharm. Bull. 26 (11): 1563–9. doi:10.1248/bpb.26.1563. PMID 14600402.
- ↑ Nagata N, Miyakawa M, Amano S, Furuya K, Yamamoto N, Nejishima H, Inoguchi K (2011). "Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties". Bioorg. Med. Chem. Lett. 21 (21): 6310–3. doi:10.1016/j.bmcl.2011.08.118. PMID 21944856.
- ↑ Nagata N, Miyakawa M, Amano S, Furuya K, Yamamoto N, Inoguchi K (2011). "Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs)". Bioorg. Med. Chem. Lett. 21 (6): 1744–7. doi:10.1016/j.bmcl.2011.01.073. PMID 21349712.
- ↑ Kinoyama I, Taniguchi N, Toyoshima A, Nozawa E, Kamikubo T, Imamura M, Matsuhisa A, Samizu K, Kawanimani E, Niimi T, Hamada N, Koutoku H, Furutani T, Kudoh M, Okada M, Ohta M, Tsukamoto S (2006). "(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist". J. Med. Chem. 49 (2): 716–26. doi:10.1021/jm050293c. PMID 16420057.